ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 336

Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up

Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Psoriatic arthritis

Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral disease using cluster analysis (CA). We aimed to determine if demographic and disease characteristics of PsA patients with at least five years of follow-up can be clustered into distinct groups.

Methods:

527 PsA patients from an observational cohort of patients seen from 1978 to 2013. Patients had at least 5 years of follow-up and genetic information in order to be included in the analysis. CA using Ward’s method was conducted to identify groups of patients based on the following characteristics at follow-up:  gender, type of psoriasis (type I or II), duration of PsA, race, family history of psoriasis, ESR, severe PASI, psoriasis vulgaris, nail disease, dactylitis, swollen joint count, damaged joint count, axial disease, presence of arthritis mutilans, presence of arthritis prior to psoriasis, HLA-B*27 and HLA-C*06. 7 clusters were formed and matched to non-overlapping arthritis patterns:  distal arthritis, oligoarthritis, polyarthritis, axial only, distal arthritis and axial, oligoarthritis & axial, and polyarthritis & axial. Comparisons between the clusters and arthritis patterns were conducted using t-tests and Chi-squared analysis.

Results:

The baseline characteristics of the 527 patients were as follows: 306 (58.1%) males, mean age at diagnosis of PsA 28.3 (14.2) yrs, mean age at first visit 42.5 (12.3) yrs, mean duration of PsA 6.8 (8.0) years, mean active joint count 10.6 (9.2), mean PASI 5.2 (8.1), mean Steinbrocker score 12.7 (25.9), HLA-B*27 94 (18%)]. At follow-up, mean age was 57.6 (12.6) yrs, mean PASI 4.6 (6.6), mean Steinbrocker score 28.0 (37.3) with an average follow-up of 15.0 (7.6) yrs. Two main clusters of patients were identified. One consisted of distal arthritis, oligoarthritis and polyarthritis and the other of axial only, distal and axial, oligoarthritis & axial, and polyarthritis & axial, thus clearly identifying patients into peripheral and axial disease. Comparison of the two clusters showed more patients with psoriasis vulgaris among patients with peripheral disease. Patients falling into the axial disease cluster had a higher prevalence of males and HLA-B*27, higher PASI, more dactylitis, higher clinically damaged joint and swollen joint count, more axial disease, more arthritis mutilans and more patients who developed arthritis first.

Conclusion: Based on patients’ characteristics at follow-up, CA analysis separated PsA patients into two predominant arthritis patterns coinciding with the results that looked at a the same cohort  at baseline with the exclusion of B27 and C6 as clustering variables. The study provides further evidence to classify patients into just two groups based on the presence or absence of axial arthritis not only at baseline but also at follow-up.

Table: Comparison of two clusters

Variable

Frequency (%) or Mean (sd)

p-value

Cluster I

Cluster II

Age at diagnosis of Ps (>40 vs. <=40)

63 (20.9%)

44 (19.5%)

0.68

Duration of PsA

21.3 (11.1)

22.5 (9.8)

0.16

Gender (Males)

149 (49.5%)

157 (69.5%)

<0.0001

Race (Caucasian vs. others)

267 (88.7%)

210 (92.9%)

0.10

Family history of Psoriasis

142 (47.7%)

116 (51.6%)

0.38

Nail disease

124 (44.6%)

106 (51.0%)

0.16

Dactylitis

6 (2.0%)

18 (8.3%)

0.001

Psoriasis vulgaris

236 (81.9%)

142 (66.4%)

<0.0001

Severe PASI (>=10)

18 (7.2%)

30 (19.4%)

0.0002

ESR

15.9 (15.8)

15.3 (17.2)

0.69

Swollen joint count

0.74 (1.72)

1.40 (3.4)

0.008

Clinically damaged joints

8.4 (12.2)

14.7 (16.4)

<0.0001

Axial disease

104 (34.9%)

177 (79.0%)

<0.0001

Presence of arthritis mutilans

76 (25.3%)

99 (43.8%)

<0.0001

Presence of arthritis prior to psoriasis

30 (10.0%)

15 (6.6%)

0.18

HLA-B*27

44 (14.6%)

50 (22.1%)

0.03

HLA-C*6

83 (27.6%)

64 (28.3%)

0.85


Disclosure:

A. Thavaneswaran,
None;

V. Chandran,
None;

D. D. Gladman,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-analysis-of-psoriatic-arthritis-patients-at-follow-up/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology